Toward Integrated Models of Infectious Diseases, Harm Reduction, and Primary Care - Top-Institutions - MDSpire

Toward Integrated Models of Infectious Diseases, Harm Reduction, and Primary Care

  • By

  • Suhanee Mitragotri

  • Aakash Reddy

  • Kevan Shah

  • David T Zhu

  • August 12, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Addiction Medicine
    • Harm Reduction

  • #2

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Addiction Medicine
    • Public Health

  • #3

    Massachusetts General Hospital (MGH) / Harvard Medical School
    Massachusetts General Hospital (MGH) / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Addiction Medicine
    • Primary Care Integration

  • #4

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Infectious Diseases
    • Addiction Medicine
    • Harm Reduction

  • #5

    University of Chicago Medicine
    University of Chicago Medicine

    Chicago, IL

    Key Differentiators

    • Infectious Diseases
    • Addiction Medicine
    • Harm Reduction

Original Source(s)

Toward Integrated Models of Infectious Diseases, Harm Reduction, and Primary Care

  • by Suhanee Mitragotri, Aakash Reddy, Kevan Shah, David T Zhu

  • August 12, 2025

Related Content

Urgent response is needed to address the stimulant-fentanyl related overdose crisis

Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey

Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents